CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer The RNA Printer is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics CureVac RNA Printer GmbH to pr

Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer

T BINGEN, Germany/ BOSTON, USA -

March 1, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines

based on messenger ribonucleic acid ("mRNA"), today announced that it has established CureVac RNA Printer GmbH, a fully-owned

CureVac company to advance The RNA Printer . The RNA Printer is CureVac's solution for integrated and automated manufacturing

of GMP-grade RNA vaccines and therapeutics. The new entity is designed as a platform and services company, providing a dedicated operational

environment to further develop and establish The RNA Printer as a manufacturing end-to-end solution. This solution will include the

main steps to manufacture mRNA vaccines or therapeutics. The platform is designed to facilitate broad access to mRNA technology and enable

mRNA product developments, e.g. for rapid supply of new mRNA-based vaccines in pandemic situations as well as patient access to advanced

and personalized mRNA-based therapies in oncology. The company will be led by Dr. Markus Bergmann, who joins CureVac RNA Printer GmbH

as General Manager on March 1, 2022.

"The successful implementation of mRNA vaccines

to address the COVID-19 pandemic has shown the tremendous potential of this technology. We are convinced that the global mRNA pipeline

will grow strongly over the next decade," said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac. "Providing access

to flexible GMP manufacturing solutions is expected to be a game changer for the speed with which new mRNA products can be advanced from

Dr. Franz-Werner Haas continues, "we warmly

welcome Dr. Markus Bergmann as the CureVac RNA Printer GmbH General Manager. His medical background as well as his experience in developing

targeted product strategies, transforming businesses and increasing business efficiency - particularly in a high-tech field -

represents a perfect fit and will create a strong momentum for the next developmental stage of The RNA Printer ."

"The RNA Printer is uniquely suited

to further strengthen and increase CureVac's footprint in the rapidly expanding RNA space," said Dr. Markus Bergmann. "The

pioneering technology behind this platform has the potential to enable the translational step from science to innovative products via

an automated solution thereby broadening access to mRNA technology. I'm excited to be part of this technology advancement and to

join this great team."

Dr. Bergmann joins CureVac RNA Printer GmbH

from ZF Group, Germany, where he held various management positions. He built his strong background in business development, product

management, finance, strategy and M&A via several leadership assignments including Rolls Royce plc., UK, and McKinsey &

Company, Germany and Asia. Dr. Bergmann started his career as a doctor at the University Hospital in T bingen, Germany, in the

Department of Hematology and Oncology after graduating from University of Heidelberg, Germany, and receiving a Doctor of Medicine in

collaboration with the German Cancer Research Center in the field of Immunology.

About The RNA Printer

is CureVac's solution for integrated and automated manufacturing of GMP-grade RNA vaccines and therapeutics engineered in collaboration

with Tesla Automation. The system is powered by a proprietary and advanced manufacturing technology designed to cover all steps for rapid

and standardized manufacturing of mRNA medicines. The RNA Printer aims to facilitate broad access to mRNA technology and to accelerate

the transition of innovative products concepts from science to the clinic across different therapeutic areas, such as new mRNA-based

vaccines in pandemic situations as well as personalized mRNA-based therapies in oncology. While The RNA Printer will

support CureVac's clinical development programs, CureVac RNA Printer GmbH will also explore opportunities to increase the versatility

and application of this technology together with external partners.

CureVac is a global biopharmaceutical company

in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing and manufacturing this

versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA

as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020,

CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on

CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19

vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline

across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its

initial public offering on the New York Nasdaq in August 2020. It is headquartered in T bingen, Germany, and employs more than 900

people at its sites in T bingen, Frankfurt, and Boston, USA.

Investor Relations Contact

Fakih, Vice President Corporate Communications and Investor Relations

Bettina J dicke-Braas, Manager Communications

CureVac, T bingen, Germany

T: +49 7071 9883-1087

Forward-Looking Statements CureVac

This press release contains statements that constitute

"forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995,

including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or

its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH

(the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples

include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies,

financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology

such as "anticipate," "intend," "believe," "estimate," "plan," "seek,"

"project," or "expect," "may," "will," "would," "could," "potential,"

"intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based

on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking

statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking

statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions

and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future

preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration

partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation,

regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects

of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel,

reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the

effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned

not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual

results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made

only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or

to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required

For further information, please reference the

company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting

EDGAR on the SEC website at www.sec.gov.